Results 11 to 20 of about 345,011 (339)

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Journal of Clinical Oncology, 2021
PURPOSE Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System.
M. Irwin, A. Naranjo, Fan F. Zhang, S. Cohn, W. London, J. Gastier-Foster, N. Ramirez, R. Pfau, S. Reshmi, Elizabeth Wagner, J. Nuchtern, S. Asgharzadeh, H. Shimada, J. Maris, R. Bagatell, Julie R. Park, M. Hogarty   +16 more
semanticscholar   +1 more source

Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome

Nature Genetics, 2023
Somatic evolutionary analysis of neuroblastoma, a pediatric tumor, proposes a common fetal time of origin. Notably, high-risk tumors exhibit early genomic instability and prolonged evolution, and this evolutionary duration predicts clinical outcomes ...
Verena Körber, Sabine A. Stainczyk, R. Kurilov, K. Henrich, B. Hero, B. Brors, F. Westermann, T. Höfer   +7 more
semanticscholar   +1 more source

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis

Nature Cancer, 2022
Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces
H. Alborzinia, Andrés F. Flórez, Sina Kreth, L. Brückner, Umut Yildiz, Moritz Gartlgruber, Dorett I Odoni, Gernot Poschet, Karolina Garbowicz, Chunxuan Shao, C. Klein, Jasmin Meier, Petra Zeisberger, Michal Nadler-Holly, M. Ziehm, F. Paul, J. Burhenne, E. Bell, Marjan Shaikhkarami, Roberto Würth, Sabine A. Stainczyk, Elisa M Wecht, Jochen Kreth, M. Büttner, Naveed Ishaque, M. Schlesner, B. Nicke, Carlo Stresemann, Maria Llamazares-Prada, J. Reiling, M. Fischer, I. Amit, M. Selbach, C. Herrmann, S. Wölfl, K. Henrich, T. Höfer, A. Trumpp, F. Westermann   +38 more
semanticscholar   +1 more source

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Nature Cancer, 2022
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms of resistance to anti-GD2 therapy.
Nathaniel W. Mabe, Min Huang, G. N. Dalton, G. Alexe, Daniel A. Schaefer, Anna C. Geraghty, A. Robichaud, A. Conway, D. Khalid, M. Mader, J. Belk, K. Ross, Michal Sheffer, Miles H. Linde, Nghi Ly, Winnie Yao, M. Rotiroti, Benjamin A. H. Smith, Marius Wernig, C. Bertozzi, Michelle Monje, C. Mitsiades, R. Majeti, Ansuman T. Satpathy, K. Stegmaier, R. Majzner   +25 more
semanticscholar   +1 more source

Immunotherapy of Neuroblastoma: Facts and Hopes

Clinical Cancer Research, 2022
While the adoption of multimodal therapy including surgery, radiation, and aggressive combination chemotherapy has improved outcomes for many children with high-risk neuroblastoma, we appear to have reached a plateau in what can be achieved with ...
John Anderson, R. Majzner, P. Sondel
semanticscholar   +1 more source

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

Nature Communications, 2022
Neuroblastoma is the most common paediatric solid tumour and prognosis remains poor for high-risk cases despite the use of multimodal treatment. Analysis of public drug sensitivity data showed neuroblastoma lines to be sensitive to indisulam, a molecular
A. Nijhuis, Arti Sikka, Orli Yogev, Lili Herendi, Cristina Balcells, Yurui Ma, E. Poon, C. Eckold, Gabriel N. Valbuena, Yuewei Xu, Yusong Liu, B. M. da Costa, Michael Gruet, Chiharu Wickremesinghe, A. Benito, Holger B. Kramer, Alex Montoya, D. Carling, E. Want, Y. Jamin, L. Chesler, Hector C. Keun   +21 more
semanticscholar   +1 more source

Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells [PDF]

, 2020
Retinoid treatment is employed during residual disease treatment in neuroblastoma, where the aim is to induce neural differentiation or death in tumour cells.
Bilip, Maja, Di Florio, Alessia, Eaton, Simon, Hart, Stephen L., Irving, Elsa, Maeshima, Ruhina, Mathiyalakan, Mayuran, Orford, Michael, Shah, Shreya, Simons, Claire, Stoker, Andrew W., Tagalakis, Aristides D.   +11 more
core   +4 more sources

MYCN Function in Neuroblastoma Development

Frontiers in Oncology, 2021
Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest ...
Jörg Otte, Cecilia Dyberg, Adena Pepich, J. Johnsen   +3 more
semanticscholar   +1 more source

CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis

Journal of Experimental & Clinical Cancer Research, 2023
Background The repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma.
Janardhan Keshav Karapurkar, Min-Seong Kim, Jencia Carminha Colaco, Bharathi Suresh, Neha Sarodaya, Dong-Ho Kim, Chang-Hwan Park, Seok-Ho Hong, Kye-Seong Kim, Suresh Ramakrishna   +9 more
doaj   +1 more source

Molecular targeting therapies for neuroblastoma: Progress and challenges

Medicinal research reviews (Print), 2020
There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is the most common pediatric solid tumor, and accounts for ~15% of childhood cancer‐related mortality.
Atif Zafar, Wei Wang, Gang Liu, Xinjie Wang, W. Xian, F. McKeon, J. Foster, Jia Zhou, Ruiwen Zhang   +8 more
semanticscholar   +1 more source